Forus has raised $150 Million in New Series C Funding

According to filings with the U.S. Securities and Exchange Commission, Forus has raised $150,000,000.00 in new Series C funding. The federal securities law requires the notice to be filed by...

Craig Etkin

October 6, 2026 2 Min Read

12 0

According to filings with the U.S. Securities and Exchange Commission, Forus has raised $150,000,000.00 in new Series C funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Bain Capital Ventures, Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel

About Forus
Forus is an AI-powered healthcare technology company that focuses on making prescription medications more accessible and affordable for patients. It provides an AI-driven prior authorization and medication access network that connects doctors, pharmacies, payers, and biopharma companies to streamline every step from prescription to therapy initiation. The platform automates complex administrative and insurance processes so that patients can start treatment faster and often at lower out-of-pocket cost. Forus positions itself as an infrastructure layer for modern medicine, aiming to accelerate access to new therapies by reducing friction between prescribers, insurers, and pharmaceutical manufacturers. The company emphasizes broad, nationwide adoption of its technology, working toward bringing its AI-powered medication access tools to doctors offices across the United States.

To learn more, visit https://forus.com/
Linkedin: https://www.linkedin.com/company/forushq/

Contact:
Sahir Jaggi, Chief Executive Officer
https://www.linkedin.com/in/sahirj